Clinical Trial · NCT06750419

89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

Overview

89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON Clinicaltrial.gov ID: NCT03849118)

Sponsor

Telix Pharmaceuticals

Phase

Phase 3

Contacts

Lily Nahidi (CONTACT)

lily.nahidi@telixpharma.com

+61 3909 33871

ClinicalTrials.gov

NCT06750419

Eligibility

Inclusion

Sufficient life expectancy to justify nephrectomy.
Consent to practise highly effective contraception until a minimum of 42 days after IV 89Zr-TLX250 administration.
Imaging evidence of a single IRM of ≤ 7 cm in largest diameter (tumour stage cT1), on SoC imaging based on national standards, not older than 90 days on Day 0, but performed before any screening procedure.
Scheduled for lesion resection as part of regular diagnostic work-up within 90 days from planned IV 89Zr-TLX250 administration.
Negative serum pregnancy tests in female patients of childbearing potential at screening. Confirmation of negative pregnancy test result from urine within 24 hours prior to receiving investigational product.

Exclusion

Exposure to murine or chimeric antibodies within the last 5 years.
Known hypersensitivity to girentuximab or desferoxamine (DFO).
A biopsy procedure only (rather than partial or total nephrectomy) is planned for histological species delineation of IRM.
Previous administration of any radionuclide within 10 half-lives of the same.
Renal mass known to be a metastasis of another primary tumour.
Chemotherapy, radiotherapy, targeted therapy or immunotherapy within 4 weeks prior to the planned administration of 89Zr -TLX250 or continuing adverse effects (\> grade 1) from such therapy (Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0).
Planned antineoplastic therapies (for the period between IV administration of 89Zr-TLX250 and imaging).
Vulnerable patients (e.g., being in detention).
Renal insufficiency with glomerular filtration rate (GFR) ≤ 45 mL/min/1.73 m².
Multiple unilateral or bilateral IRM.
Exposure to any experimental diagnostic or therapeutic drug within 4 weeks or 5 half-lives (whichever is longer) from the date of planned administration of 89Zr-TLX250.
Active non-renal malignancy requiring therapy during the time frame of the study participation.
Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic), that may interfere with the objectives of the study or with the safety or compliance of the study subject, as judged by the investigator.
Women who are pregnant or breastfeeding.

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…